Investigations into the mechanism of action and potential in idiopathic pulmonary fibrosis of the novel ruthenium based therapeutic BOLD-100
Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease lung disease with unknown cause. There are limited treatment options for IPF and investigations into new treatment options is needed. BOLD-100 is a clinical-stage small molecule that is currently being investigated as a treatment option in oncology and viral infections. The pathway that BOLD-100 impacts, the unfolded protein response, is important in IPF and therefore this project’s objective is to use preclinical models to test whether BOLD-100 can affect development of IPF. The interns will gain experience using a range of different models to test an industry backed compound and will interaction with industry veterans at the partner organization, Bold Therapeutics. Bold Therapeutics will benefit by utilizing the expertise of the Ask laboratory to potentially expand the potential of BOLD-100 into IPF.